抗转录中介因子1-γ抗体是成人皮肌炎合并恶性肿瘤的血清学标志物

doi:10.16150/j.1671-2870.2020.03.013

摘要/Abstract

摘要：

目的： 研究血清抗转录中介因子1-γ（transcriptional intermediary factor 1-γ, TIF1-γ）抗体在诊断皮肌炎（dermatomyositis, DM）和临床无肌病性皮肌炎（clinically amyopathic dermatomyositis, CADM）合并恶性肿瘤中的价值。方法： 2016年1月至2019年12月间,收集上海交通大学医学院附属瑞金医院皮肤科病房收治的223例DM和CADM患者[包括209例成人DM（107例）和CADM（102例）,5例青少年DM（juvenile DM, JDM）和9例青少年JCADM（juvenile CADM, JCADM）]的临床资料。成人DM和成人CADM分别被分为恶性肿瘤组和无肿瘤组。初诊时血清用酶联免疫吸附测定法检测患者血清抗TIF1-γ抗体,分别比较成人DM和成人CADM患者中恶性肿瘤与无肿瘤患者之间抗TIF1-γ抗体的阳性率,进一步比较抗TIF1-γ抗体阳性与抗体阴性患者之间恶性肿瘤的发生率。结果： ①成人DM和CADM中恶性肿瘤共42例（20.1%）,占前3位的分别是鼻咽癌、乳腺癌和肺癌。JDM和JCADM患者中无一例发生恶性肿瘤。②成人DM和CADM中有74例（74/209,35.4%）血清抗TIF1-γ抗体阳性,其中DM患者抗TIF1-γ抗体阳性率33.6%（36/107）,CADM患者抗TIF1-γ抗体阳性率37.3%（38/102）。5例JDM患者中,无一例抗TIF1-γ抗体阳性;9例JCADM患者中,3例抗TIF1-γ抗体阳性。③成人DM中,恶性肿瘤患者的抗TIF1-γ抗体阳性率显著高于无肿瘤患者[26/35(74.3%)比10/72(13.9%), P<0.000 1];抗TIF1-γ抗体阳性患者恶性肿瘤的发生率显著高于阴性患者[26/36 (72.2%)比9/71 (12.7%), P<0.000 1]。成人CADM中,恶性肿瘤患者与无肿瘤患者之间抗TIF1-γ抗体的阳性率差异无统计学意义[4/7比34/95(35.8%), P=0.420];抗TIF1-γ抗体阳性与抗体阴性患者之间恶性肿瘤的发生率差异无统计学意义[4/38(10.5%)比3/64(4.7%), P=0.420]。结论： 抗TIF1-γ抗体阳性与成人DM患者恶性肿瘤的发生相关,而与成人CADM患者恶性肿瘤发生无关。抗TIF1-γ抗体可能是成人DM合并恶性肿瘤的血清标志物,对于抗TIF1-γ抗体阳性的成人DM患者需要加强恶性肿瘤筛查。

关键词: 皮肌炎, 转录中介因子1-γ, 肿瘤

Abstract:

Objective: To explore significance of anti-transcriptional intermediary factor 1-γ (TIF1-γ) antibody detection in diagnosing ermatomyositis (DM) malignancy or clinically amyopathic dermatomyositis (CADM) accompanied by malignancy diseases. Methods: A total of hospitalized 223 patients were enrolled at Department of Dermatology, Ruijin Hospital during Jan. 2016 to Dec. 2019, including 107 cases of adult DM, 102 cases of adult CADM, 5 cases of juvenile DM, and 9 cases of juvenile CADM. DM patients were divided into malignant DM group and non-malignant DM group, and so were the CADM patients. Enzyme-linked immunosorbent assay(ELISA) was used to detect serum anti-TIF1-γ antibodies in patients at first visit. The positive rates of anti-TIF1-γ antibody were compared between malignant DM group and non-malignant DM as well as between malignant CADM group and non-malignant CADM group. Results： It revealed that 35 adult DM and 7 adult CADM patients were diagnosed as having malignant neoplasia, and nasopharyngeal carcinoma, breast cancer and lung cancer were on the top three of cancer-associated myositis in our cohort, however, there was no malignancy detected in JDM and JCADM patients. Seventy-four (35.4%) adult patients had serum anti-TIF1-γ antibody detected, including 36 cased of DM (33.6%) and 38 cases of CADM (37.3%). Serum anti-TIF1-γ antibody was positive in 3 cases of JCADM (33.3%), but none in total of 5 cases of JDM. The positive rate of anti-TIF1-γ antibody in DM patients with malignant tumor was significantly higher than those without malignant tumor[26/35(74.3%) vs 10/72(13.9%), P<0.000 1]. The incidence of malignant tumor in patients with positive anti-TIF1-γ antibody was significantly higher than those with negative antibody[26/36(72.2%) vs 9/71(12.7%), P<0.000 1]. However there was no significant difference in the positive rate of anti-TIF1-γ antibody between patients with malignant tumor and without malignant tumor [4/7 vs 34/95(35.8%), P=0.420] in adult CADM. There was no statistically significant difference in the incidence of malignancy between anti-TIF1-γ antibody-positive and antibody-negative patients[4/38 (10.5%) vs 3/64(4.7%), P=0.420]. Conclusions： Serum anti-TIF1-γ antibody correlates with the occurrence of malignancy diseases in DM, but has no relationship with malignancy diseases in CADM. Thus, anti-TIF1-γ antibody might be the serum biomarker for DM associated with malignancy, and oncology screening should be intensified in adult DM patients with positive anti-TIF1-γ antibody.

Key words: Dermatomyositis, Transcriptional intermediary factor 1-γ, Malignancy

中图分类号:

R751

夏群力, 刁立诚, 吴海曦, 薛珂, 吴丹, 杜联军, 郑捷, 曹华, 黎皓. 抗转录中介因子1-γ抗体是成人皮肌炎合并恶性肿瘤的血清学标志物[J]. 诊断学理论与实践, 2020, 19(03): 274-278.

XIA Qunli, DIAO Licheng, WU Haixi, XUE Ke, WU Dan, DU Lianjun, ZHENG Jie, CAO Hua, LI Hao. Anti-transcriptional intermediary factor 1-γ antibody serves as a serum biomarker for dermatomyositis accompanied by malignancy diseases[J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 274-278.

图/表 1

参考文献 18

[1]	Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study[J]. Br J Cancer, 2001, 85(1):41-45. doi: 10.1054/bjoc.2001.1699 URL
[2]	Zhang W, Jiang SP and Huang L. Dermatomyositis and malignancy: Aretrospective study of 115 cases[J]. Eur Rev Med Pharmacol Sci, 2009, 13(2):77-80.
[3]	Azuma K, Yamada H, Ohkubo M, et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis[J]. Mod Rheumatol, 2011, 21(2):178-183. doi: 10.3109/s10165-010-0362-y URL
[4]	Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: A population-based study[J]. Lancet, 2001, 357(9250):96-100. pmid: 11197446
[5]	Chen D, Yuan S, Wu X, et al. Incidence and predictive factors for malignancies with dermatomyositis: A cohort from southern China[J]. Clin Exp Rheumatol, 2014, 32(5):615-621.
[6]	Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts[J]. Medicine (Baltimore), 2018, 97(2):e9639. doi: 10.1097/MD.0000000000009639 URL
[7]	Wang J, Guo G, Chen G, et al. Meta-analysis of the association of dermatomyositis and polymyositis with cancer[J]. Br J Dermatol, 2013, 169(4):838-847. doi: 10.1111/bjd.12564 pmid: 23909921
[8]	Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kdprotein is associated with dermatomyositis[J]. Arthritis Rheum, 2006, 54(11):3682-3689. doi: 10.1002/art.22164 URL
[9]	Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: An association with malignancy[J]. Rheumatology (Oxford), 2007, 46(1):25-28. doi: 10.1093/rheumatology/kel161 URL
[10]	Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292(7):344-347. doi: 10.1056/NEJM197502132920706 URL
[11]	Sontheimer RD, Miyagawa S. Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis[J]. J Am Acad Dermatol, 2003, 48(5):797-798. pmid: 12734516
[12]	Chen DY, Chen YM, Lan JL, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: The Epstein-Barr virus connection?[J]. J Clin Virol, 2010, 49(4):290-295. doi: 10.1016/j.jcv.2010.08.015 URL
[13]	Ogawa-Momohara M, Muro Y, Mitsuma T, et al. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients[J]. Clin Exp Rheumatol, 2018, 36(6):990-995. pmid: 29745874
[14]	Selva-O’Callaghan A, Trallero-Araguás E, Grau-Junyent JM, et al. Malignancy and myositis: Novel autoantibodies and new insights[J]. Curr Opin Rheumatol, 2010, 22(6):627-632. doi: 10.1097/BOR.0b013e32833f1075 pmid: 20827204
[15]	Ueda-Hayakawa I, Hamaguchi Y, Okiyama N, et al. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: Clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy[J]. Br J Dermatol, 2019, 180(4):881-887. doi: 10.1111/bjd.17098 pmid: 30120913
[16]	Ueki M, Kobayashi I, Takezaki S, et al. Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies[J]. Mod Rheumatol, 2019, 29(2):351-356. doi: 10.1080/14397595.2018.1452353 URL
[17]	Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult-Japanese patients with dermatomyositis: A multicenter cross-sectional study[J]. Arch Dermatol, 2011, 147(4):391-398. doi: 10.1001/archdermatol.2011.52 pmid: 21482889
[18]	Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: Their clinical and pathogenic significance in disease expression[J]. Rheumatology(Oxford), 2009, 48(6):607-612. doi: 10.1093/rheumatology/kep078 URL

组别	抗TIF1-γ抗体阳性（n）	抗TIF1-γ抗体阴性（n）	灵敏度	特异度	阳性预测值	阴性预测值
成人DM（n=107）			74.3%	86.1%	72.2%	87.3%
恶性肿瘤组（n=35）	26	9
无肿瘤组（n=72）	10	62
成人CADM（n=102）			4/7	64.2%	10.5%	95.3%
恶性肿瘤组（n=7）	4	3
无肿瘤组（n=95）	34	61